Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2015 / Articles / Jun / How Does it Feel?
Discovery & Development Formulation

How Does it Feel?

When it comes to topical formulations, I firmly believe that patients care about the way a cream or ointment feels – and that it plays a very important role in compliance.

By James Humphrey 06/26/2015 1 min read

Share

When my colleagues and I are considering a new dermatological formulation, we focus on four areas: solubility, stability, sensory and delivery. We ensure that the API is at least partially soluble in the formulation and stable physically and chemically. We also consider whether the patient will actually apply the formulation and ensure that the active pharmaceutical ingredient (API) can reach the required target. The pharmaceutical industry puts a huge amount of resource into the solubility, stability and delivery aspects of derma formulation, but the sensory aspect is something that is largely overlooked, if not ignored altogether. Is it really right to leave the aesthetics of a formulation to an afterthought?

This point was very well made by a professor of dermatology, Steven Feldman, who said “I think vehicle effects on delivery through the stratum corneum are less important than the fact that the patient actually puts the medicine on” (1). It’s an irrefutable fact that no drug is bioavailable when it stays in the container. I’m not saying that the formulation aesthetics should be considered more important than bioavailability, or indeed other aspects of designing a new formulation, but that all factors need to be taken into consideration to design a truly successful treatment. I have frequently heard the comment, “If the patient has the disease they will use the treatment”, and for very severe conditions I imagine this is quite true. However, for milder conditions and many over-the-counter formulations I think this assumption is made with the mindset of a scientist. As a scientist, I know that the activity of the API often takes time; I know that I must keep applying the product for the correct number of times per day to get results. But do all users think like this? Do patients always finish their course of antibiotics, even after they feel better? Does the patient always apply the ointment three times a day? I’m less than convinced.

Compliance or concordance is essential to create a successful treatment, but there are a lot of different facets required to achieve it. Where do we start? I think that one area that the world of healthcare can learn from is cosmetics. Cosmetics are based around creating a consumer belief in the product. I’m certainly not proposing that a good cosmetic story replaces the rigorous science needed to develop a topical pharma product, but we should consider some of the psychology used. I started my formulation career in cosmetics. In those days, I would formulate skincare products with three aspects in mind. Firstly, make sure the formulation you offer does not feel horrible; finding something that the majority of people would agree that they strongly like is difficult, and yet most people readily agree on what feels unpleasant to apply. Secondly, make the consumer believe there is an improvement in the first few minutes of application. Thirdly, make sure the formulation meets the consumer expectations in the long term.

The best example of this is an anti-aging cream. For daywear, you develop a light formulation that quickly absorbs into the skin, and for night-time use you create a more substantial-feeling product. Ingredients are added to the formulation to give what are referred to as 'instant effects'; for anti-aging creams these will give the appearance of smoother skin. This element is really important as without this immediate ‘evidence’ of an effect it’s unlikely that the user will stick with the formulation. Maintaining use of the product actually allows the emollients and anti-aging actives to achieve their long-term effect. I’m not suggesting that healthcare formulations require instant effects but there is something to be taken from the idea. When starting to formulate, take some time to consider the aesthetics. Can you really expect someone to apply a heavy, greasy formulation made of petrolatum or high-molecular-weight PEG twice a day? Does the formulation convince the user that it’s doing some good? Can you expect a patient with sore and broken skin to apply and rub in a thick, paste-like formulation? I believe pharmaceutical formulators need to consider a wider selection of ingredients, moving away from the trusted topical formulations used for decades, and formulate products with cosmetically acceptable aesthetics. Only then will a patient happily use the product every day as instructed, and we can move closer to achieving complete concordance.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. Medscape, “Improving Adherence, Improving Outcomes: An Expert Interview With Steven R. Feldman”, http://www.medscape.org/viewarticle/588417

About the Author(s)

James Humphrey

James Humphrey is a Market Applications Specialist working in the research laboratories of Croda in the UK. He focuses on what excipients can do to improve pharmaceutical formulations, whether it’s enhancing bioavailability, stability or aesthetics. James says, “What I love about formulation is the neverending challenge of working out how seemingly small and insignificant changes to a formulation result in massive variation in performance.”

More Articles by James Humphrey

False

Advertisement

Recommended

False

Related Content

What About the Kids?
Formulation
What About the Kids?

December 3, 2014

0 min read

Since the late 1990s, new regulations have given us the opportunity to address the needs of the most vulnerable and demanding patients – children...

Squid-Inspired Drug Delivery
Drug Delivery Dosage Forms Formulation
Squid-Inspired Drug Delivery

April 3, 2025

4 min read

Here’s how researchers took lessons from cephalopods to develop a new capsule that can deliver drugs, including insulin and siRNA, orally

Schizophrenia and the Future of Long-Acting Therapeutics
Formulation Dosage Forms Drug Delivery
Schizophrenia and the Future of Long-Acting Therapeutics

March 11, 2025

5 min read

Long-acting injectables help with adherence, but what if an unfolding pill could provide an oral option?

The Power of Industry and Academic Collaboration
Drug Discovery Formulation
The Power of Industry and Academic Collaboration

March 13, 2025

6 min read

Purdue University’s Young Institute is tackling pharma’s toughest challenges— from mRNA stability to aseptic manufacturing.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.